Seroquel XR Shortage Update: What Patients Need to Know in 2026

If you've had trouble filling your Seroquel XR prescription recently, you may be wondering whether there's an official drug shortage — or what exactly is going on. This article provides the most current information on Seroquel XR (quetiapine fumarate extended-release) availability in 2026, the causes of pharmacy-level stock gaps, and what steps you can take as a patient.

Is Seroquel XR in Shortage in 2026?

As of 2026, Seroquel XR (quetiapine fumarate extended-release) is not listed on the FDA Drug Shortage Database as a nationally designated shortage medication. Multiple generic manufacturers continue to produce quetiapine XR, and the brand-name Seroquel XR (now distributed in the U.S. by Cheplapharm) is also available. The overall U.S. drug shortage landscape has also improved: ASHP reported that the number of new drug shortages reached its lowest level in nearly 20 years in 2025.

However, pharmacy-level stock gaps remain a real problem for many quetiapine XR patients — particularly for specific strengths at specific chains. "Not in shortage" does not mean "reliably available at every pharmacy."

History of Quetiapine XR Availability in the U.S.

Brand-name Seroquel XR was introduced by AstraZeneca and initially approved by the FDA in 2007. Generic quetiapine XR became available after patents began expiring around 2012-2013, and multiple manufacturers entered the market. The shift to a multi-manufacturer generic market generally increased supply and reduced prices dramatically. There has not been a widespread FDA-designated shortage of quetiapine XR in recent years, unlike some other psychiatric medications (such as amphetamines).

The most notable supply event in recent years has been AstraZeneca transferring the Seroquel XR brand rights to Cheplapharm Arzneimittel GmbH, a German specialty pharma company focused on maintaining marketed legacy brands. This transition had some patients temporarily unsure about brand availability, but does not represent a shortage of the medication itself.

Why Do Patients Still Experience Stock Gaps in 2026?

Even without an active shortage, quetiapine XR stock gaps happen because:

• Extremely high prescription volume. Quetiapine is among the most prescribed psychiatric medications in the U.S., with millions of prescriptions written annually. This creates relentless demand that can temporarily outpace local pharmacy stock.
• Strength-specific demand imbalances. The 50 mg, 150 mg, and 300 mg tablets are prescribed most frequently. These strengths sell out faster than others, causing localized gaps even when 200 mg and 400 mg remain available.
• Chain-supplier contracts. Large pharmacy chains source generics from preferred wholesalers. When that wholesaler backorders a strength, the chain can't dispense it — even if other manufacturers have inventory.
• Generic market consolidation. Thin generic drug margins have caused some manufacturers to exit the quetiapine XR market. Fewer manufacturers means less production redundancy — any single-manufacturer quality issue has outsized impact on supply.

What to Do If You Can't Fill Your Seroquel XR Prescription

Here is a prioritized action plan for patients who can't fill their Seroquel XR:

1. Do not stop taking quetiapine XR abruptly. Contact your prescriber immediately if you are running out. They can authorize a partial supply, provide samples, or help bridge with quetiapine IR.
2. Use medfinder to check which pharmacies near you have your specific strength in stock. medfinder calls pharmacies on your behalf and texts you results.
3. Try independent pharmacies. They often have stock when chains don't because they use different wholesale suppliers.
4. Ask your current pharmacy for a partial fill to hold you over while you locate the full supply.
5. Consider mail-order pharmacy for future fills. Seroquel XR is not a controlled substance, so mail-order is permitted for 90-day supplies, often at lower cost through insurance plans.

Is the Situation Likely to Improve?

Yes — the broad U.S. drug shortage environment is improving in 2026, and quetiapine XR specifically is not facing structural production constraints. The stock gaps patients encounter are primarily supply chain logistics issues at the pharmacy and distribution level, not manufacturing failures. These types of gaps tend to be shorter in duration and more localized than true manufacturing-driven shortages. The most important thing patients can do is search broadly across pharmacies rather than waiting for one location to restock.

Read more: Why Is Seroquel XR So Hard to Find? [Explained for 2026]